GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » ROE % Adjusted to Book Value

IsoPlexis (IsoPlexis) ROE % Adjusted to Book Value : -155.37% (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is IsoPlexis ROE % Adjusted to Book Value?

IsoPlexis's ROE % for the quarter that ended in Dec. 2022 was -231.50%. IsoPlexis's PB Ratio for the quarter that ended in Dec. 2022 was 1.49. IsoPlexis's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 was -155.37%.

IsoPlexis ROE % Adjusted to Book Value Historical Data

The historical data trend for IsoPlexis's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IsoPlexis ROE % Adjusted to Book Value Chart

IsoPlexis Annual Data
Trend Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
- - -27.61 -77.53

IsoPlexis Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.30 -76.44 -106.16 -96.75 -155.37

Competitive Comparison of IsoPlexis's ROE % Adjusted to Book Value

For the Medical Devices subindustry, IsoPlexis's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IsoPlexis's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, IsoPlexis's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where IsoPlexis's ROE % Adjusted to Book Value falls into.


IsoPlexis ROE % Adjusted to Book Value Calculation

IsoPlexis's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-115.52% / 1.49
=-77.53%

IsoPlexis's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-231.50% / 1.49
=-155.37%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IsoPlexis ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of IsoPlexis's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

IsoPlexis (IsoPlexis) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IsoPlexis Corp (NAS:ISO) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
VAPO AZYO LHDX LUCD SONX EYES CTSO LNSR CFMS PAVM ABT MDT SYK EW BSX SZSE:300760 DXCM ZBH STE ALGN
Traded in Other Exchanges
N/A
Address
35 North East Industrial Road, Branford, CT, USA, 06405
Website
https://www.isoplexis.com
IsoPlexis Corp is a developer of a single-cell detection system designed to accelerate insights in the field of cancer. It designed a platform to reveal functional protein biology and cellular signaling networks at single-cell resolution to accelerate the development of advanced medicines.
Executives
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
John Strahley officer: Chief Financial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Sean Mackay director, officer: Chief Executive Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rew Richard W. Ii officer: SVP, GC & Secretary 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
James R Heath director C/O ISOPLEXIS, 35 NE INDUSTRIAL RD, BRANFORD CT 06405
Michael Egholm director 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Jason W. Myers director C/O ARCHERDX, INC., 2477 55TH STREET, SUITE 202, BOULDER CO 80301
John G. Conley director 396 GREAT MEADOWS RD, CONCORD MA 01742-1803
Gregory P. Ho director, 10 percent owner C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Peter Siesel officer: Chief Commercial Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Jing Zhou officer: Chief Scientific Officer 35 NORTH EAST INDUSTRIAL ROAD, BRANFORD CT 06405
Rajesh T. Khakhar officer: VP, Finance 35 NORTH INDUSTRIAL ROAD, BRANFORD CT 06405
Northpond Capital Gp, Llc 10 percent owner 4 BRATTLE STREET, FLOOR 3, CAMBRIDGE MA 02138
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003